Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04645446
Other study ID # 049/SI
Secondary ID 2019-000747-27
Status Completed
Phase Phase 2
First received
Last updated
Start date February 18, 2021
Est. completion date October 27, 2022

Study information

Verified date March 2021
Source SIFI SpA
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Multicenter, Randomized, Double-Masked, Placebo-Controlled, Parallel-Group, Phase 2 clinical trial. The study objective is to evaluate the safety and efficacy of two different concentrations (0.5% and 1%) of progesterone topical gel compared to placebo, when administered twice a day for 3 months (12 weeks) in patients diagnosed with moderate to severe dry eye syndrome.


Recruitment information / eligibility

Status Completed
Enrollment 96
Est. completion date October 27, 2022
Est. primary completion date October 27, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Patients (male or female) = 18 years of age. 2. Able and willing to provide voluntary written Informed Consent prior to any study related procedure. 3. Patients must be diagnosed with any type of dry eye at least 3 months before screening (Visit 0). 4. Have all the following in the same eye at Visit 0: - Fluorescein staining (Cornea) on NEI (National Eye Institute) grading scale > 3 - Average Tear Film Break up Time = 5 seconds - Schirmer Test (without anesthesia) = 1 and < 10mm 5. Be able and willing to follow instructions, including participation in all study assessments and visits, according to the opinion of the investigator. Exclusion Criteria: 1. Comorbidity with other severe or chronic conditions that in the judgment of the investigator will interfere with study assessment, such as such as glaucoma, active neuronal trigeminal disease, neuralgia. 2. Best corrected visual acuity (BCVA) baseline <20/200. 3. Condition or history other than ocular that, in the opinion of the investigator, may interfere significantly with the patient's participation in the study, such as dementia, psychosis, Parkinson's disease (interference). 4. Patient using a contact ocular lens within 7 days prior to administration of the first dose and not willing to cease using them during all study duration. 5. Female patients who are pregnant, nursing an infant, or planning a pregnancy or lactating at Screening Visit. 6. Females who are of childbearing potential and not taking adequate contraceptive precautions are excluded from the trial. Females of childbearing potential taking acceptable non-hormonal contraceptive precautions can be included (See Note A). 7. Males with partners who are pregnant or lactating or of childbearing potential and are unwilling to use condoms for the duration of the study. 8. A known adverse reaction and/or sensitivity to the study drug or its components. 9. Use of topical ocular cyclosporine, corticosteroids or any other topical anti-inflammatory treatments within 15 days prior to Visit 0 and during all study duration. 10. Routine use (more than twice a week) of a chlorinated swimming pool during the study period 11. Unwilling or unable to cease using during the study period the forbidden medications: - Any topical ocular ointments or gels - Topical and systemic glaucoma therapies - Systemic drugs with anticholinergic activity: anticonvulsants, antihistamines, antipsychotics, antidepressants, antimuscarinics, anti-Parkinson agents, cardiovascular agents (disopyramide), gastrointestinal agents, muscle relaxants, respiratory medications (pseudoephedrine, theophylline) - Lipidic artificial tears and artificial tears with preservative. 12. Unwilling to cease the use of sunscreen on the forehead or eye area during the study period. 13. Habitual cigarette smokers (tobacco, vapor cigarettes, marijuana), smoking more than 4 cigarettes per day. 14. Participation in another clinical study at the same time as the present and within 30 days prior to Visit 0.

Study Design


Intervention

Drug:
Pro-ocular gel
Topical gel in multidose formulation to be applied laterally to the forehead twice a day, morning and night for 3 months
Placebo gel
Topical gel in multidose formulation to be applied laterally to the forehead twice a day, morning and night for 3 months

Locations

Country Name City State
Italy Ospedale San Marco - Azienda Ospedaliera Universitaria Catania
Italy A.O.U. Careggi Firenze - SOD Oculistica Florence
Italy Azienda Ospedaliera Universitaria Policlinico G. Martino - UOC di Oftalmologia Messina
Italy Ospedale Luigi Sacco Polo Universitario - Oculistica Milan

Sponsors (1)

Lead Sponsor Collaborator
SIFI SpA

Country where clinical trial is conducted

Italy, 

Outcome

Type Measure Description Time frame Safety issue
Primary Corneal Fluorescein Staining Mean change from baseline (Visit 1 pre-dose) in corneal fluorescein staining assessed by NEI scale at Week 12 (Day 84) (with Last Observation Carried Forward (LOCF) imputation) Week 12 (Day 84) (with Last Observation Carried Forward (LOCF) imputation)
Primary SANDE questionnaire Mean change from baseline (Visit 1 pre-dose) in sum of frequency and intensity of dryness/irritation patient feeling assessed by SANDE questionnaire at Week 12 (Day 84) (with LOCF imputation) Week 12 (Day 84) (with Last Observation Carried Forward (LOCF) imputation)
Secondary Corneal fluorescein staining Mean change from baseline (Visit 1 pre-dose) in corneal fluorescein staining assessed by NEI scale at Week 12 (Day 84). Week 12 (Day 84)
Secondary SANDE questionnaire Mean change from baseline (Visit 1 pre-dose) in sum of frequency and intensity of dryness/irritation patient feeling assessed by SANDE questionnaire at Week 12 (Day 84). Week 12 (Day 84)
Secondary Conjunctival fluorescein staining Mean change from baseline (Visit 1 pre-dose) in conjunctival fluorescein staining assessed by NEI scale at Week 12 (Day 84) (with LOCF imputation). Week 12 (Day 84) (with Last Observation Carried Forward (LOCF) imputation)
Secondary Conjunctival fluorescein staining Mean change from baseline (Visit 1 pre-dose) in conjunctival fluorescein staining assessed by NEI scale at Week 12 (Day 84). Week 12 (Day 84)
Secondary Corneal fluorescein staining Mean change from baseline (Visit 1 pre-dose) in corneal fluorescein staining assessed by NEI scale at Week 2, 4, 8 (Day 14, 28, 56) as intermediate study visits. Week 2, 4, 8 (Day 14, 28, 56)
Secondary SANDE questionnaire Mean change from baseline (Visit 1 pre-dose) in sum of frequency and intensity of dryness/irritation patient feeling assessed by SANDE questionnaire at Week 2, 4, 8, 16 (Day 14, 28, 56,114) as intermediate study visits. Week 2, 4, 8, 16 (Day 14, 28, 56,114)
Secondary Conjunctival fluorescein staining Mean change from baseline (Visit 1 pre-dose) in conjunctival fluorescein staining assessed by NEI scale at Week 2, 4, 8 (Day 14, 28, 56) as intermediate study visits. Week 2, 4, 8 (Day 14, 28, 56)
Secondary Non-Invasive Keratograph Tear Film Break Up (NIKBUT) Time (NIKBUT) Mean change from baseline (Visit 1 pre-dose) in Non-Invasive Keratograph Tear Film Break Up Time (NIKBUT) at each applicable post-baseline visit [Week 2, 4, 8, 12 (Day 14, 28, 56, 84)]. Week 2, 4, 8, 12 (Day 14, 28, 56, 84)
Secondary Fluorescein Tear Film Break Up Time (TBUT) Mean change from baseline (Visit 1 pre-dose) in Fluorescein Tear Film Break Up Time (TBUT) at Week 12 (Day 84). Week 12 (Day 84)
Secondary Tear meniscus height (TMH) Mean change from baseline (Visit 1 pre-dose) in Tear meniscus height (TMH) at each applicable post-baseline visit [Week 2, 4, 8, 12 (Day 14, 28, 56, 84)]. Week 2, 4, 8, 12 (Day 14, 28, 56, 84)]
Secondary Schirmer test Mean change from baseline (Visit 0 Screening) in Schirmer test at Week 4 (Day 28) and at Week 12 (Day 84). Week 4 (Day 28) and Week 12 (Day 84)
Secondary Dry Eye-Related Quality-of-Life (DEQS) questionnaire Impact of dry eye on quality of life by using Dry Eye-Related Quality-of-Life (DEQS) questionnaire. Each applicable post baseline visit
Secondary Visual Analogue Scale Absolute score of each symptom item in Visual Analogue Scale to each post baseline visit. Each applicable post baseline visit
Secondary Visual Analogue Scale Mean change from baseline (Visit 1 pre-dose) in Visual Analogue Scale 7 symptoms items to each applicable post-baseline visit [Week 2, 4, 8, 12 (Day 14, 28, 56, 84)]. Week 2, 4, 8, 12 (Day 14, 28, 56, 84)
Secondary Corneal Sensitivity Mean change from baseline (Visit 1 pre-dose) in Corneal Sensitivity to each applicable postbaseline visit [Week 4, 12 (Day 28, 84)]. Week 4, 12 (Day 28, 84)
Secondary Slit Lamp Examination Mean change from baseline (Visit 0 Screening) in Slit Lamp Examination to each applicable post-baseline visit [Week 2, 4, 8, 12 (Day 14, 28, 56, 84)]. Week 2, 4, 8, 12 (Day 14, 28, 56, 84)
See also
  Status Clinical Trial Phase
Completed NCT03216096 - Assessing Safety and Efficacy of DE-089 Ophthalmic Solution in Patients With Dry Eye Disease Phase 1
Completed NCT05825599 - PMCF Study to Evaluate Performance and Safety of "HPMC-based Eyedrops" Used to Relieve Dry Eye Symptoms N/A
Completed NCT04656197 - The Ocular Microbiome in Patients With Dry Eye Disease
Completed NCT05031806 - Evaluation of the Safety, Tolerability and Efficacy of iNexin™ for the Treatment of the Signs and Symptoms Associated With Dry Eye Disease Phase 1
Completed NCT03688802 - Efficacy of OC-01 Nasal Spray on Goblet Cell and Meibomian Gland Stimulation Phase 2
Completed NCT05213156 - Concentration of Ofloxacin Into the Aqueous Humour of Patients With Dry Eye Disease Phase 4
Completed NCT04548427 - Study to Evaluate the Efficacy and Safety of CKD-352 Phase 3
Completed NCT06176651 - Evaluation of Miebo (Perfluorohexyloctane) Eyedrops in Habitual Contact Lens Wearers Phase 4
Completed NCT02254265 - Phase 2/3 Dose-Ranging Study of the Safety and Efficacy of OTX-101 in the Treatment of Keratoconjunctivitis Sicca Phase 2/Phase 3
Completed NCT00395759 - The Visual Effect of an Investigational Artificial Tear in the Tear Layer. N/A
Completed NCT00680108 - A Study to Determine the Safety and Tolerability of Escalating Doses of INS365 Ophthalmic Solution Phase 2
Recruiting NCT06064071 - Clinical Study Evaluating Nordlys™ SWT IPL for Dry Eye Disease (DED) Due to MGD N/A
Completed NCT04139122 - Safety, PK and Efficacy Study of SJP-0132 in Subjects With Dry Eye Disease Phase 1/Phase 2
Not yet recruiting NCT06375343 - Study to Evaluating PRO-240 Ophthalmic Solution Compared to Optive® Phase 1
Completed NCT01468168 - A Study Assessing the Safety and Efficacy of DE-101 Ophthalmic Suspension in Dry Eye Patients Phase 2
Completed NCT01014078 - A Four Week Study of Azithromycin Ophthalmic Solution, 1% Versus Placebo in Subjects With Dry Eye Disease Phase 4
Completed NCT00799682 - Exploratory Study Comparing Signs and Symptoms in Patients With Ocular Hypertension or Glaucoma Using Xalatan R® or Travatan Z® Phase 4
Completed NCT05082974 - Investigator Initiated Study to Assess the Efficacy of OC-01 (Varenicline) Nasal Spray on Signs and Symptoms of Dry Eye Disease Following Laser-assisted in Situ Keratomileusis (LASIK) Phase 3
Recruiting NCT06146881 - Effectiveness of Diquafosol Prophylactic Therapy to Prevent Dry Eye Disease for Cataract Surgery Patients in Indonesia Phase 2
Completed NCT03292809 - CyclASol for the Treatment of Signs and Symptoms of Dry Eye Disease (DED) Phase 2/Phase 3